297 related articles for article (PubMed ID: 31771640)
21. Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
Wang F; Yang Y; Du X; Zhu X; Hu Y; Lu C; Sui L; Zhao H; Song K; Yao Q
BMC Cancer; 2023 Jan; 23(1):44. PubMed ID: 36639622
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
[TBL] [Abstract][Full Text] [Related]
23. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.
Vang R; Gown AM; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Am J Surg Pathol; 2006 Sep; 30(9):1130-9. PubMed ID: 16931958
[TBL] [Abstract][Full Text] [Related]
24. Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case Report.
Van Rompuy AS; Vanderstichele A; Vergote I; Moerman P
Int J Gynecol Pathol; 2018 May; 37(3):290-295. PubMed ID: 28463910
[TBL] [Abstract][Full Text] [Related]
25. SATB2 Versus CDX2: A Battle Royale for Diagnostic Supremacy in Mucinous Tumors.
Brettfeld SM; Ramos BD; Berry RS; Martin DR; Hanson JA
Arch Pathol Lab Med; 2019 Sep; 143(9):1119-1125. PubMed ID: 30838879
[TBL] [Abstract][Full Text] [Related]
26. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
Groisman GM; Meir A; Sabo E
Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
[TBL] [Abstract][Full Text] [Related]
27. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas.
Ji H; Isacson C; Seidman JD; Kurman RJ; Ronnett BM
Int J Gynecol Pathol; 2002 Oct; 21(4):391-400. PubMed ID: 12352188
[TBL] [Abstract][Full Text] [Related]
28. A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.
Chelariu-Raicu A; Holley E; Mayr D; Klauschen F; Wehweck F; Rottmann M; Kessler M; Kaltofen T; Czogalla B; Trillsch F; Mahner S; Schmoeckel E
Int J Gynecol Cancer; 2022 May; 32(5):662-668. PubMed ID: 35185017
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic value of SATB2, CK7 and CK20 in colorectal cancer].
Lyn J; Wang Y; Wang F; Shen M; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):578-81. PubMed ID: 26705182
[TBL] [Abstract][Full Text] [Related]
30. Dual Stain With SATB2 and CK20/Villin Is Useful to Distinguish Colorectal Carcinomas From Other Tumors.
Li Z; Rock JB; Roth R; Lehman A; Marsh WL; Suarez A; Frankel WL
Am J Clin Pathol; 2018 Feb; 149(3):241-246. PubMed ID: 29471325
[TBL] [Abstract][Full Text] [Related]
31. Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation.
Park KJ; Bramlage MP; Ellenson LH; Pirog EC
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):8-11. PubMed ID: 18776815
[TBL] [Abstract][Full Text] [Related]
32. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
[TBL] [Abstract][Full Text] [Related]
33. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine.
Lin F; Shi J; Zhu S; Chen Z; Li A; Chen T; Wang HL; Liu H
Arch Pathol Lab Med; 2014 Aug; 138(8):1015-26. PubMed ID: 24437456
[TBL] [Abstract][Full Text] [Related]
34. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
Elias KM; Labidi-Galy SI; Vitonis AF; Hornick JL; Doyle LA; Hirsch MS; Cramer DW; Drapkin R
Gynecol Oncol; 2014 Feb; 132(2):328-33. PubMed ID: 24342438
[TBL] [Abstract][Full Text] [Related]
35. Immunophenotypic Comparison of Neoplasms of the Appendix, Right Colon, and Left Colon in Search of a Site-Specific Phenotypic Signature.
Mesa H; Manivel JC; Larson WS; Dachel SK; Reinink AR; Jessurun J
Int J Surg Pathol; 2020 Feb; 28(1):20-30. PubMed ID: 31271071
[No Abstract] [Full Text] [Related]
36. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
Zhang YJ; Chen JW; He XS; Zhang HZ; Ling YH; Wen JH; Deng WH; Li P; Yun JP; Xie D; Cai MY
EBioMedicine; 2018 Feb; 28():62-69. PubMed ID: 29396302
[TBL] [Abstract][Full Text] [Related]
37. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
38. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas.
Kim CJ; Baruch-Oren T; Lin F; Fan XS; Yang XJ; Wang HL
J Clin Pathol; 2016 Dec; 69(12):1046-1050. PubMed ID: 27169755
[TBL] [Abstract][Full Text] [Related]
39. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors.
Zhao LH; Chen C; Mao CY; Xiao H; Fu P; Xiao HL; Wang G
Pathol Res Pract; 2019 Jul; 215(7):152448. PubMed ID: 31133441
[TBL] [Abstract][Full Text] [Related]
40. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.
Lagendijk JH; Mullink H; Van Diest PJ; Meijer GA; Meijer CJ
Hum Pathol; 1998 May; 29(5):491-7. PubMed ID: 9596273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
